AbbVie, Inc.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00287Y1091
USD
228.71
-1.53 (-0.66%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About AbbVie, Inc. stock-summary
stock-summary
AbbVie, Inc.
Pharmaceuticals & Biotechnology
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
Company Coordinates stock-summary
Company Details
1 N Waukegan Rd , NORTH CHICAGO IL : 60064-1802
stock-summary
Tel: 1 847 9327900
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 265 Schemes (29.78%)

Foreign Institutions

Held by 646 Foreign Institutions (15.65%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Richard Gonzalez
Chairman of the Board, Chief Executive Officer
Mr. Glenn Tilton
Lead Independent Director
Dr. Robert Alpern
Independent Director
Ms. Roxanne Austin
Independent Director
Mr. William Burnside
Independent Director
Mr. Thomas Freyman
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
15,423 Million
(Quarterly Results - Jun 2025)
Net Profit:
931 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 377,734 Million (Large Cap)

stock-summary
P/E

23.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

150.59%

stock-summary
Debt Equity

-349.80

stock-summary
Return on Equity

-8,165.01%

stock-summary
Price to Book

-2,064.12